Syngene International
NSE:SYNGBangalore, India· Est.
India’s leading integrated CRDMO delivering full‑spectrum drug development services for pharma and biotech.
Is this your company? Claim your profile to update info and connect with investors.
Claim profileAI Company Overview
India’s leading integrated CRDMO delivering full‑spectrum drug development services for pharma and biotech.
OncologyImmunologyRare DiseasesInfectious DiseasesCentral Nervous System
Technology Platform
SynVent integrated drug discovery platform combined with dedicated centers (e.g., CAPS) and advanced manufacturing capabilities for small molecules, biologics, and next‑gen modalities.
Opportunities
Expansion of biologics fill‑finish capacity and AI‑driven drug design services will unlock new high‑value contracts with global pharma and emerging biopharma firms.
Risk Factors
Intense competition from larger global CROs and regulatory challenges in biologics manufacturing could pressure margins and client retention.
Competitive Landscape
Syngene competes with CRO giants such as Charles River, WuXi, and Catalent; its differentiation lies in integrated end‑to‑end platforms, strong ESG credentials, and a growing biologics manufacturing footprint.